Understanding the Senolytic and Senomorphic Effects of Zoledronate in an Ageing Mouse Model
Bisphosphonates (BPs) have been used to treat patients with osteoporosis and osteopenia for over a quarter of a century. BP treatment has been shown to:
- Reduce skeletal re-modelling rate
- Strengthen bones
- Reduce fracture rates
There are two classes of BPs; non-nitrogenous such as Clodronate and nitrogenous such as Zoledronate. Bisphosphonates work by inhibiting farnesyl pyrophosphate synthase, leading to osteoclast apoptosis.